Interstitial Lung Disease / Pulmonary Fibrosis
DC 6825Medical Rationale
Rheumatoid arthritis (RA) is a systemic autoimmune disease that produces extra-articular manifestations in 40% of patients, with the lungs being the most common extra-articular target. RA-associated interstitial lung disease (RA-ILD) develops when the same immune dysregulation driving synovial inflammation, autoantibody production (RF, anti-CCP), Th1/Th17 activation, and pro-inflammatory cytokine release (TNF-alpha, IL-6), targets the pulmonary interstitium. Immune complexes deposit in the alveolar capillary membrane, triggering macrophage activation and fibroblast proliferation that produces progressive pulmonary fibrosis. The usual interstitial pneumonia (UIP) pattern predominates, identical histologically to idiopathic pulmonary fibrosis. RA-ILD develops in 10-30% of RA patients and is the second leading cause of death in RA after cardiovascular disease.
Key Studies
Bongartz T et al. (2010) Arthritis Rheum (RA-associated interstitial lung disease, incidence and mortality); Olson AL et al. (2011) Am J Respir Crit Care Med (RA-ILD prevalence and prognosis).
Filing Tips
High-resolution chest CT demonstrating interstitial lung disease pattern (ground-glass opacities, honeycombing, traction bronchiectasis). Pulmonary function tests showing restrictive pattern with reduced DLCO. Rheumatology and pulmonology records documenting RA diagnosis preceding ILD. Rheumatology nexus letter addressing systemic autoimmune mechanism. If methotrexate is used for RA, the nexus letter should address whether ILD is disease-related or medication-related (both are valid secondary pathways). File under DC 6825 (diffuse interstitial fibrosis), severe ILD with DLCO <40% predicted can warrant 100% rating.
